ProCE Banner Activity

Audio From Expanding HBV Treatment Candidacy

Audio

Hear expert insights on the evidence for treating patients with immune-tolerant CHB and what ALT threshold should define HBV treatment candidacy in this on-demand audio commentary.

Released: September 05, 2019

Expiration: September 03, 2020

No longer available for credit.

Share

Faculty

Ira M. Jacobson

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead

Faculty Disclosure

Primary Author

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received funds for research support from Assembly Biosciences, Bristol-Myers Squibb, Enanta, Genfit, Gilead Sciences, and Janssen and consulting fees from AbbVie, Arrowhead, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, Novo Nordisk, Siemens, and Spring Bank.